13F Pro quality score
Rank #2,144 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
14 transactions in INSM reported by 2 members of Congress under the STOCK Act, most recent trade Jun 10, 2026. Reported transactions, not recommendations.
INSMED Inc (INSM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INSM at 39.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,144 of 2,925 stocks — the bottom half of the AI-ranked universe. INSM scores in the top quartile across revenue growth (96.9), institutional flow (83.0). Areas of concern include balance sheet strength (5.6) and free cash flow (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), INSMED Inc reports quarterly revenue of $425.5M, net income of $-13.2M, an operating margin of -0.4%. INSM trades on the Nasdaq exchange and files with the SEC under CIK 1104506. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INSMED Inc directly from SEC EDGAR.